Wave Life Sciences Ltd. (WVE) Earnings Call Transcripts

Wave Life Sciences Ltd.'s Latest Earnings Call - May 18, 2026

In the Q1 2026 earnings call for Wave Life Sciences Ltd. (WVE:US), management provided a positive update on the RestorAATion-2 trial of WVE-006, an RNA editing oligonucleotide targeting alpha-1 antitrypsin deficiency (AATD). The trial showed significant reductions in Z-AAT levels and increases in M-AAT levels, with Z-AAT reduced by approximately 70% and M-AAT reaching levels above the protective threshold. Revenue and earnings details were not disclosed, but management signaled an upcoming regulatory feedback expected in mid-2026 regarding an accelerated approval pathway for WVE-006, which could serve as a significant catalyst for the stock.

Reported metrics

Guidance from management

Management expects to receive regulatory feedback on an accelerated approval pathway for WVE-006 in mid-2026, which could expedite the drug's market entry and enhance its commercial potential.

What management said

Sam, it's a wonderful question. However, I must say Dr. Hogarth is in the middle of 2 other -- he's actually going to an alpha-1 back and just stepped out. We're trying to see if we can bring him back in for questions. But if not, we're happy to find him. I think he's already gone to the alpha-1 foundation recept but I apologize. But we'll get -- we'll connect him with you.

Yes. So that was the update that I gave, which is we see about a 16 micromolar increase. So those are the examples that we continue to see that increase in that relative proportion, as we said, of M and Z, is the same.

What analysts pressed on

Analysts expressed concerns regarding the long-term efficacy of WVE-006 compared to existing therapies and the need for robust clinical endpoints to support full approval. Questions were raised about the potential for higher dosing regimens and the dynamics of AAT production over time.

Main topics on the call

• Positive Clinical Trial Results — Management reported that WVE-006 achieved a 70% reduction in Z-AAT levels and increased M-AAT levels to 11.9 micromolar with biweekly dosing, exceeding the protective threshold of 11 micromolar. Dr. Bolno stated, "With o...
• Safety Profile — WVE-006 was reported to be generally safe and well tolerated, with no serious adverse events and no clinically relevant changes in liver function tests. This differentiates it from other therapies that have shown liver t...
• Regulatory Pathway — Management is on track for regulatory feedback on an accelerated approval pathway for WVE-006 expected in mid-2026. This could significantly impact the stock as it may lead to faster market entry. Dr. Bolno noted, "We’re...
• Market Potential — The global AATD market is projected to grow from $1.7 billion to $5 billion by 2031, driven by increasing diagnosis rates and treatment uptake. This positions WVE-006 as a potential market leader. Bolno stated, "AATD rem...

Read the full Wave Life Sciences Ltd. transcript (May 18, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 52 Wave Life Sciences Ltd. earnings call transcripts on record, spanning March 2, 2020 to July 30, 2026. Based on this history, Wave Life Sciences Ltd. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

WVE

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

52

First call

March 2, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly